Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 23, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.9K

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review.

Mihai Dorin Vartolomei1,2, Mesut Remzi1, Harun Fajkovic1

  • 1Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.

Journal of Clinical Medicine
|October 27, 2022
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCG Vaccination Modulates Long-Term TNF-α and sCD40L in COVID-19: An Exploratory Longitudinal Study.

International journal of general medicine·2026
Same author

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.

Prostate cancer and prostatic diseases·2026
Same author

Pathology of the upper urinary tract tumours: Histologic subtypes, genetics, biomarker testing.

Histopathology·2025
Same author

Focal Therapy Using High-Intensity Focused Ultrasound for Low- and Intermediate-Risk Prostate Cancer: Results from a Prospective, Multicenter Feasibility Trial.

Cancers·2025
Same author

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.

International journal of cancer·2025
Same author

Trend and Cancer-Specific Prevalence of Kidney Stones Among US Cancer Survivors, 2007-2020.

Current oncology (Toronto, Ont.)·2025
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles
This summary is machine-generated.

Robot-assisted partial nephrectomy (RAPN) demonstrates excellent oncologic outcomes for T1 renal masses, comparable to open and laparoscopic approaches. Long-term survival data is still emerging but initial results are highly promising for cancer control.

Area of Science:

  • Urology
  • Surgical Oncology
  • Robotic Surgery

Background:

  • Robot-assisted partial nephrectomy (RAPN) is increasingly utilized for cT1 renal masses.
  • Guidelines recommend open (OPN), laparoscopic (LPN), or robotic partial nephrectomy (PN) equally.
  • This review focuses on oncologic outcomes of RAPN.

Purpose of the Study:

  • To systematically analyze reported oncologic outcomes from representative Robot-assisted partial nephrectomy (RAPN) series.
  • To assess the efficacy of RAPN in comparison to other partial nephrectomy techniques.

Main Methods:

  • Systematic literature search of Web of Science, PubMed, and ClinicalTrials.gov up to August 1, 2022.
  • Inclusion criteria: T1 renal cell carcinoma (RCC), prospective or retrospective studies, RAPN, and minimum 48-month follow-up.
Keywords:
cancer-specific survivalmetastasisnephron-sparing surgeryoverall survivalpartial nephrectomyrenal cancerrobot-assisted

More Related Videos

Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

3.7K
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.7K

Related Experiment Videos

Last Updated: Aug 23, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.9K
Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

3.7K
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.7K
  • Data extraction focused on oncologic outcomes such as positive surgical margins, recurrence, metastasis, and survival rates.

    • Main Results:

    • Positive surgical margin rates ranged from 0% to 10.5%.
    • Local recurrence rates were up to 3.6%, and distant metastases up to 6.4%.
    • 5-year cancer-free survival (CFS) was 86.4%-98.4%, cancer-specific survival (CSS) was 90.1%-100%, and overall survival (OS) was 82.6%-97.9%.

    Conclusions:

    • Retrospective and prospective data indicate favorable oncologic outcomes following RAPN.
    • RAPN demonstrates comparable oncologic performance to OPN and LPN.
    • Long-term (10-year) survival data for RAPN is not yet available.